Abstract
Chronic kidney disease (CKD) is frequently accompanied by disturbances in bone metabolism, leading to a heightened risk of fractures. The receptor for advanced glycation end-products (RAGE) plays a pivotal role in the pathogenesis of CKD. This case-control study included 50 CKD patients and 50 healthy controls to examine the association between RAGE gene polymorphisms (rs2070600 and rs2071288) and bone metabolism markers. Serum parathyroid hormone (PTH), alkaline phosphatase (ALP), and vitamin D levels were measured as indicators of bone metabolism. CKD patients exhibited significantly higher ALP (317.54 ± 21.95 U/L) and PTH (331.33 ± 17.11 pg/mL) levels, along with lower vitamin D (26.92 ± 6.64 ng/mL) compared to controls (all P < 0.05). The CC genotype of rs2070600 was more prevalent among patients (52%) and was associated with an increased risk of CKD (OR = 2.79, 95% CI: 1.21–6.39, P = 0.014). In contrast, no significant association was found between rs2071288 and CKD risk. Notably, individuals carrying CC or CT genotypes for rs2070600 and rs2071288 had higher levels of PTH and ALP, alongside significantly lower levels of vitamin D. The RAGE gene's rs2070600 polymorphism may be connected to abnormalities in bone metabolism and the advancement of CKD. These results indicate that rs2070600 genotyping may be useful in identifying high-risk patients; however, additional research is required to validate its clinical significance.